Skip to main content
Premium Trial:

Request an Annual Quote

AnPac Bio to Raise $5M in Private Placement

NEW YORK — AnPac Bio-Medical Science said on Monday that it has struck a deal to sell $5 million of shares and warrants to a group of nine investors.

Under the terms of the private placement, AnPac Bio will sell 28,571,428 newly issued Class A ordinary shares at a price of $3.50 per American Depositary Share, $.175 per ordinary share. For each Class A ordinary share purchased, the buyer will also receive from AnPac Bio two unregistered warrants that are exercisable at $4.20 each within two years.

Shanghai-based AnPac Bio said that the sale is expected to take place within three months.

Last week, AnPac Bio announced that it has regained compliance with the Nasdaq's minimum $1 per share bid requirement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.